EICHOR
● Active Not Recruiting
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC
Condition: Head and Neck Squamous Cell Carcinoma (HNSCC) · Sponsor: Inhibrx Biosciences, Inc
About this study
This seamless phase 2/3 randomized controlled study will evaluate the efficacy and safety of the hexavalent OX40 agonist antibody INBRX-106 combined with the anti-PD-1 antibody pembrolizumab versus pembrolizumab (+ placebo in phase 3) as first-line treatment for patients with locally advanced recurrent or metastatic head and neck squamous cell carcinoma (R/M HSNSCC) incurable by local therapies, expressing PD-L1 with a combined proportion score (CPS) ≥20.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (87)
| City of Hope Medical Center | Duarte, California, United States | — |
| Los Angeles Cancer Network (LACN) | Los Angeles, California, United States | — |
| UC Davis | Sacramento, California, United States | — |
| Medical Oncology Associates of San Diego | San Diego, California, United States | — |
| Sarcoma Oncology Center | Santa Monica, California, United States | — |
| ChristianaCare Health Services | Newark, Delaware, United States | — |
| University of Florida UF Health Cancer Center | Gainesville, Florida, United States | — |
| The Oncology Institute of Hope & Innovation | Miami, Florida, United States | — |
| Mid Florida Hematology and Oncology Center | Orange City, Florida, United States | — |
| Cleveland Clinic Florida, The Maroone Cancer Center | Weston, Florida, United States | — |
| University of Illinois Cancer Center | Chicago, Illinois, United States | — |
| Norton Cancer Institute | Louisville, Kentucky, United States | — |
+ 75 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06295731